187 related articles for article (PubMed ID: 19067367)
41. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.
Rhew DC; Bernal M; Aguilar D; Iloeje U; Goetz MB
Clin Infect Dis; 2003 Oct; 37(7):959-72. PubMed ID: 13130409
[TBL] [Abstract][Full Text] [Related]
42. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
43. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents.
Soh CH; Oleske JM; Brady MT; Spector SA; Borkowsky W; Burchett SK; Foca MD; Handelsman E; Jiménez E; Dankner WM; Hughes MD;
Lancet; 2003 Dec; 362(9401):2045-51. PubMed ID: 14697803
[TBL] [Abstract][Full Text] [Related]
44. Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.
Smith GH; Boulassel MR; Klien M; Gilmore N; MacLeod J; LeBlanc R; René P; Routy JP; Lalonde RG
HIV Clin Trials; 2005; 6(2):63-72. PubMed ID: 15983890
[TBL] [Abstract][Full Text] [Related]
45. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
46. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
Hoffmann F; Notheis G; Wintergerst U; Eberle J; Gürtler L; Belohradsky BH
Pediatr Infect Dis J; 2000 Jan; 19(1):47-51. PubMed ID: 10643850
[TBL] [Abstract][Full Text] [Related]
47. The Decline in HIV-1 Drug Resistance in Heavily Antiretroviral-Experienced Patients Is Associated with Optimized Prescriptions in a Treatment Roll-Out Program in Mexico.
Calva JJ; Larrea S; Tapia-Maltos MA; Ostrosky-Frid M; Lara C; Aguilar-Salinas P; Rivera H; Ramírez JP
AIDS Res Hum Retroviruses; 2017 Jul; 33(7):675-680. PubMed ID: 28094565
[TBL] [Abstract][Full Text] [Related]
48. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
49. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
Gottlieb GS; Badiane NM; Hawes SE; Fortes L; Toure M; Ndour CT; Starling AK; Traore F; Sall F; Wong KG; Cherne SL; Anderson DJ; Dye SA; Smith RA; Mullins JI; Kiviat NB; Sow PS;
Clin Infect Dis; 2009 Feb; 48(4):476-83. PubMed ID: 19143530
[TBL] [Abstract][Full Text] [Related]
50. Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.
Neilan AM; Karalius B; Patel K; Van Dyke RB; Abzug MJ; Agwu AL; Williams PL; Purswani M; Kacanek D; Oleske JM; Burchett SK; Wiznia A; Chernoff M; Seage GR; Ciaranello AL;
JAMA Pediatr; 2017 May; 171(5):450-460. PubMed ID: 28346597
[TBL] [Abstract][Full Text] [Related]
51. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
52. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.
De Milito A; Catucci M; Venturi G; Romano L; Incandela L; Valensin PE; Zazzi M
J Med Virol; 1999 Feb; 57(2):140-4. PubMed ID: 9892398
[TBL] [Abstract][Full Text] [Related]
53. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
54. Protease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA): A Randomized Controlled Trial.
Jespersen S; Hønge BL; Krarup H; Medstrand P; Sørensen A; Medina C; Té DDS; Correira FG; Erikstrup C; Østergaard L; Wejse C; Laursen AL;
J Acquir Immune Defic Syndr; 2018 Nov; 79(3):386-393. PubMed ID: 30044302
[TBL] [Abstract][Full Text] [Related]
55. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
56. Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome.
Balint GA
Pharmacol Ther; 2001 Jan; 89(1):17-27. PubMed ID: 11316511
[TBL] [Abstract][Full Text] [Related]
57. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
58. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002.
Moore RD; Keruly JC; Gebo KA; Lucas GM
J Acquir Immune Defic Syndr; 2005 Jun; 39(2):195-8. PubMed ID: 15905736
[TBL] [Abstract][Full Text] [Related]
59. Prevalence and Predictors of Distal Symmetric Polyneuropathy in Patients with HIV/AIDS not on Highly Active Anti Retroviral Therapy (HAART).
Gupta PK; Varun V; Mahto SK; Hansraj ; Anand KS; Taneja RS; Shrama N; Vishal A
J Assoc Physicians India; 2020 Sep; 68(9):23-26. PubMed ID: 32798341
[TBL] [Abstract][Full Text] [Related]
60. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.
Lucas GM; Chaisson RE; Moore RD
Ann Intern Med; 1999 Jul; 131(2):81-7. PubMed ID: 10419445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
